✦ LIBER ✦

PERSEPHONE is a randomised phase III controlled trial comparing six months of trastuzumab to the standard 12 months in patients with HER2 positive early breast cancer

✍ Scribed by Earl, Helena; Cameron, David; Miles, David; Wardley, Andrew; Ogburn, Emma; Vallier, Anne-Laure; Loi, Shrushma; Hiller, Louise; Dunn, Janet

Book ID: 122109123
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 40 KB
Volume: 40
Category: Article
ISSN: 0748-7983
DOI: 10.1016/j.ejso.2014.02.033

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6 months versus 12 months of adjuvant tr

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

✍ Pivot, Xavier; Romieu, Gilles; Debled, Marc; Pierga, Jean-Yves; Kerbrat, Pierre; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 358 KB

Treatment with trastuzumab for 1 year af

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

✍ Luca Gianni; Urania Dafni; Richard D Gelber; Evandro Azambuja; Susanne Muehlbaue 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 322 KB

Subcutaneous versus intravenous administ

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

✍ Gustavo Ismael; Roberto Hegg; Susanne Muehlbauer; Dominik Heinzmann; Bert Lum; S 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 245 KB